J&J-Pharmacyclics' Imbruvica is second breakthrough therapy to win FDA approval

11/13/2013 | Reuters

Johnson & Johnson and Pharmacyclics received the FDA's approval to market Imbruvica, or ibrutinib, for treatment of patients with mantle cell lymphoma who have received at least one other therapy. The approval makes ibrutinib the second drug with breakthrough therapy status to receive the FDA's nod. The drug is also under regulatory review for chronic lymphocytic leukemia.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Director of Operations - GBS
Mayo Clinic
Rochester, MN
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Senior Vice President, Clinical Affairs & Strategic Partnerships
America's Health Insurance Plans (AHIP)
Washington, DC